# 2025年10月27日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. P21阳性衰老基质细胞促进前列腺癌免疫抑制和进展，可通过衰老细胞清除疗法逆转

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41135083](https://pubmed.ncbi.nlm.nih.gov/41135083)
**期刊：** Cancer discovery
**PMID：** 41135083
**DOI：** 10.1158/2159-8290.CD-25-1212

### 第一部分 原文与翻译

**英文原标题：** P21-positive senescent stromal cells promote prostate cancer immune suppression and progression that can be reversed by senolytic therapy.

**英文摘要原文：**
Cellular senescence is a well-established tumor-suppressive cell cycle arrest program. However, chronic inflammation through the senescence-associated secretory phenotype (SASP) can alternatively drive immune suppression and cancer progression. Using prostate cancer patient samples and murine models, we find p16+ and p21+ senescent cells accumulate throughout malignant progression and associate with immune suppression. Single cell sequencing revealed p16 and p21 mark distinct epithelial and stromal senescent populations, with p21+ non-tumor cells expressing the highest SASP. p21+ stromal cell removal blocked the SASP to reverse immune suppression and slow tumor growth. Senolytic BCL-xL inhibitor treatment could clear p21+ stromal senescent cells, reactivating anti-tumor CD8+ T cell immunity and inhibiting prostate tumor progression in mice. Suppression of BCL-xL or p21 also potentiated anti-PD-1 ICB in preclinical prostate cancer models. Our findings demonstrate that targeting p21+ senescent stromal populations can yield therapeutic benefits in advanced prostate cancer through activating anti-tumor immunity and enhancing immunotherapy outcomes.

**中文摘要译文：**
细胞衰老是一种公认的肿瘤抑制性细胞周期停滞程序。然而，通过衰老相关分泌表型（SASP）引发的慢性炎症可替代性地驱动免疫抑制和癌症进展。利用前列腺癌患者样本和小鼠模型，我们发现p16+和p21+衰老细胞在整个恶性进展过程中积累，并与免疫抑制相关。单细胞测序显示p16和p21标记了不同的上皮和基质衰老群体，其中p21+非肿瘤细胞表达最高的SASP。清除p21+基质细胞可阻断SASP，从而逆转免疫抑制并减缓肿瘤生长。衰老细胞清除剂BCL-xL抑制剂治疗能够清除p21+基质衰老细胞，重新激活抗肿瘤CD8+ T细胞免疫，并抑制小鼠前列腺肿瘤进展。抑制BCL-xL或p21也能增强临床前前列腺癌模型中抗PD-1免疫检查点阻断的效果。我们的研究结果表明，靶向p21+衰老基质群体可通过激活抗肿瘤免疫和增强免疫治疗效果，在晚期前列腺癌中产生治疗益处。

### 第二部分 AI 大师评价

本研究深入探讨了衰老细胞在前列腺癌进展中的双重作用，创新性地识别了p21+基质衰老细胞作为驱动免疫抑制的关键群体。研究采用前列腺癌患者样本和小鼠模型结合单细胞测序技术，发现p21+非肿瘤细胞表达最高的SASP，并通过清除这些细胞成功逆转了免疫抑制。该研究的重大突破在于揭示了靶向特定衰老细胞亚群可增强免疫治疗效果，为晚期前列腺癌治疗提供了新的联合治疗策略。然而，研究主要基于临床前模型，其临床转化效果仍需进一步验证。

---

## 2. 伊布替尼联合利妥昔单抗对比免疫化疗治疗初治套细胞淋巴瘤患者的随机、开放标签、2/3期优效性试验（ENRICH研究）

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41052510](https://pubmed.ncbi.nlm.nih.gov/41052510)
**期刊：** Lancet (London, England)
**PMID：** 41052510
**DOI：** 10.1016/S0140-6736(25)01432-1

### 第一部分 原文与翻译

**英文原标题：** Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.

**英文摘要原文：**
BACKGROUND: Ibrutinib, a Bruton tyrosine kinase inhibitor, prolongs progression-free survival when added to immunochemotherapy as first line treatment. The ENRICH trial compared the chemotherapy-free combination of ibrutinib and the anti-CD20 antibody rituximab (ibrutinib-rituximab) with standard immunochemotherapy (R-CHOP [rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone] or bendamustine-rituximab) in patients 60 years and older with untreated mantle-cell lymphoma.

METHODS: This randomised, open-label, phase 2/3 superiority trial was performed at 66 sites in the UK, Sweden, Norway, Finland, and Denmark. Patients 60 years and older with untreated mantle-cell lymphoma (Ann-Arbor stage II-IV disease, an Eastern Cooperative Oncology Group performance-status score of 0-2) were randomly assigned to receive either rituximab plus immunochemotherapy or ibrutinib-rituximab in a 1:1 ratio, stratified by investigator choice of immunochemotherapy. Patients randomly allocated to the ibrutinib-rituximab (intervention) group received 560 mg oral ibrutinib daily in combination with six to eight cycles of 375 mg/m intravenous rituximab on day 1 of each cycle in the matched schedule of the pre-randomisation choice of immunochemotherapy (every 21 days for R-CHOP or every 28 days for rituximab-bendamustine). R-CHOP comprised 750 mg/m of cyclophosphamide, 50 mg/m of doxorubicin, and 1·4 mg/m vincristine on day 1 of each 21-day cycle, with 100 mg prednisolone on days 1-5 of each cycle. Rituximab-bendamustine comprised 90 mg/m of bendamustine on days 1 and 2 of each cycle, in combination with 375 mg/m rituximab on day 1 of each cycle. All responding patients in both groups at the end of induction received maintenance rituximab administered every 8 weeks for 2 years, and patients allocated to the intervention group continued ibrutinib until disease进展 or unacceptable toxicity. The primary outcome was investigator-assessed progression-free survival, stratified by immunochemotherapy choice and analysed in the intention-to-treat population. The trial was registered with EudraCT (2015-000832-13) and is closed for recruitment.

FINDINGS: Between Feb 15, 2016, and June 30, 2021, 397 patients were randomly allocated to immunochemotherapy (control) or ibrutinib-rituximab (intervention). Of the 397, 107 (27%) were pre-allocated to the immunochemotherapy choice of R-CHOP and 290 (73%) were pre-allocated to rituximab-bendamustine. In total, 198 were allocated to the control group (53 to R-CHOP and 145 to bendamustine-rituximab) and 199 were allocated to intervention. The median age was 74 years (IQR 70-77) for the intervention group and 74 years (70-78) in the control group. 296 patients (75%) were male and 101 patients (25%) were female; ethnicity data were not collected. At a median follow-up of 47·9 months, the median progression-free survival of ibrutinib-rituximab was superior to immunochemotherapy, with an adjusted hazard ratio (HR) of 0·69 (95% CI 0·52-0·90); p=0·0034. For those with pre-randomisation choice R-CHOP, the HR was 0·37 (0·22-0·62), and with bendamustine-rituximab, the HR was 0·91 (0·66-1·25). Across induction and maintenance, 67% of patients assigned to ibrutinib-rituximab and 70% of patients receiving immunotherapy reported grade 3 or above adverse events.

INTERPRETATION: To our knowledge, this is the first randomised trial in untreated mantle-cell lymphoma to demonstrate significant improvement in progression-free survival for ibrutinib-rituximab compared to immunochemotherapy. This study suggests that ibrutinib-rituximab should be considered a new standard of care option for first-line treatment of older patients with mantle-cell lymphoma.

FUNDING: Cancer Research UK (C7627/A17938) and Johnson and Johnson Pharmaceuticals.

**中文摘要译文：**
背景：伊布替尼是一种布鲁顿酪氨酸激酶抑制剂，作为一线治疗加入免疫化疗时可延长无进展生存期。ENRICH试验在60岁及以上初治套细胞淋巴瘤患者中比较了不含化疗的伊布替尼联合抗CD20抗体利妥昔单抗（伊布替尼-利妥昔单抗）与标准免疫化疗（R-CHOP[利妥昔单抗-环磷酰胺、多柔比星、长春新碱和泼尼松龙]或苯达莫司汀-利妥昔单抗）的疗效。

方法：这项随机、开放标签、2/3期优效性试验在英国、瑞典、挪威、芬兰和丹麦的66个中心进行。60岁及以上初治套细胞淋巴瘤患者（Ann-Arbor分期II-IV期疾病，东部肿瘤协作组体能状态评分0-2分）按1:1比例随机分配接受利妥昔单抗联合免疫化疗或伊布替尼-利妥昔单抗治疗，按研究者选择的免疫化疗方案进行分层。随机分配到伊布替尼-利妥昔单抗（干预）组的患者每日口服560mg伊布替尼，联合6-8个周期的375mg/m²静脉注射利妥昔单抗（每个周期第1天给药），给药时间表与随机化前选择的免疫化疗方案相匹配（R-CHOP每21天一次，利妥昔单抗-苯达莫司汀每28天一次）。R-CHOP方案包括每个21天周期的第1天给予750mg/m²环磷酰胺、50mg/m²多柔比星和1.4mg/m²长春新碱，以及每个周期第1-5天给予100mg泼尼松龙。利妥昔单抗-苯达莫司汀方案包括每个周期第1和2天给予90mg/m²苯达莫司汀，联合每个周期第1天给予375mg/m²利妥昔单抗。诱导治疗结束后，两组中所有有反应的患者均接受维持性利妥昔单抗治疗，每8周一次，持续2年，分配到干预组的患者继续服用伊布替尼直至疾病进展或出现不可接受的毒性。主要结局是研究者评估的无进展生存期，按免疫化疗选择分层并在意向治疗人群中进行分析。该试验已在EudraCT注册（2015-000832-13）并已停止招募。

结果：2016年2月15日至2021年6月30日期间，397例患者被随机分配到免疫化疗（对照组）或伊布替尼-利妥昔单抗（干预组）。在397例患者中，107例（27%）预先分配到R-CHOP免疫化疗选择，290例（73%）预先分配到利妥昔单抗-苯达莫司汀。总计198例分配到对照组（53例接受R-CHOP，145例接受苯达莫司汀-利妥昔单抗），199例分配到干预组。干预组中位年龄为74岁（IQR 70-77），对照组为74岁（70-78）。296例患者（75%）为男性，101例患者（25%）为女性；未收集种族数据。中位随访47.9个月时，伊布替尼-利妥昔单抗的中位无进展生存期优于免疫化疗，调整后风险比（HR）为0.69（95% CI 0.52-0.90）；p=0.0034。对于随机化前选择R-CHOP的患者，HR为0.37（0.22-0.62），对于选择苯达莫司汀-利妥昔单抗的患者，HR为0.91（0.66-1.25）。在诱导和维持治疗期间，分配到伊布替尼-利妥昔单抗的患者中有67%和接受免疫治疗的患者中有70%报告了3级或以上不良事件。

解读：据我们所知，这是首个在初治套细胞淋巴瘤中证明伊布替尼-利妥昔单抗相比免疫化疗在无进展生存期方面有显著改善的随机试验。本研究提示，伊布替尼-利妥昔单抗应被视为老年套细胞淋巴瘤患者一线治疗的新标准治疗选择。

资助：英国癌症研究中心（C7627/A17938）和强生制药公司。

### 第二部分 AI 大师评价

本研究是套细胞淋巴瘤治疗领域的重要突破性研究。核心目的是比较无化疗的伊布替尼联合利妥昔单抗方案与传统免疫化疗在老年初治套细胞淋巴瘤患者中的疗效。研究采用多中心随机对照设计，纳入397例60岁以上患者，中位随访近4年。关键发现显示伊布替尼-利妥昔单抗显著改善无进展生存期（HR=0.69），特别是在R-CHOP亚组中获益更明显（HR=0.37）。该研究的创新性在于首次证实无化疗靶向联合方案可作为老年套细胞淋巴瘤一线治疗新标准，具有重要临床价值。局限性包括对苯达莫司汀亚组获益有限，且安全性数据相当，为临床治疗决策提供了有力证据。

---

## 3. 骨质疏松症

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40946719](https://pubmed.ncbi.nlm.nih.gov/40946719)
**期刊：** Lancet (London, England)
**PMID：** 40946719
**DOI：** 10.1016/S0140-6736(25)01385-6

### 第一部分 原文与翻译

**英文原标题：** Osteoporosis.

**英文摘要原文：**
Osteoporotic fractures are one of the most common and consequential diseases of advanced ageing and many antifracture therapies are widely available but largely underused. This Seminar presents an updated approach to osteoporosis consultation, drawing upon published evidence and collaborative expert opinion to place the data in a pragmatic and useful context for clinicians. New evidence on osteoporosis screening recommendations, fracture-risk assessment, intervention decisions, nutrition-based therapies, and antiresorptive and anabolic therapies are discussed, along with practical approaches to treatment in the oldest old, those with chronic kidney disease, and patients who continue to fracture despite therapy. Patient safety is emphasised by providing an overview of advice on safe discontinuation of denosumab in those who require it.

**中文摘要译文：**
骨质疏松性骨折是老年期最常见且后果严重的疾病之一，许多抗骨折治疗方法虽然广泛可用但使用严重不足。本次研讨会基于已发表的证据和协作专家意见，提出了一种更新的骨质疏松症诊疗方法，为临床医生提供了实用且有效的临床背景。讨论了骨质疏松症筛查建议、骨折风险评估、干预决策、营养治疗以及抗骨吸收和促骨形成治疗的新证据，同时提供了针对高龄老人、慢性肾病患者以及治疗后仍持续骨折患者的实用治疗方法。通过概述需要停用地诺单抗患者的安全停药建议，强调了患者安全性。

### 第二部分 AI 大师评价

本研究旨在为骨质疏松症的临床诊疗提供全面更新的循证医学指导。研究采用文献综述与专家共识相结合的方法，系统整合了最新的临床证据。核心贡献在于将骨质疏松筛查、风险评估、治疗决策等关键环节整合为实用的临床路径，特别关注了高龄老人、慢性肾病等特殊人群的治疗策略。该研究的创新性体现在对地诺单抗安全停药等重要临床问题的前瞻性指导，具有重要的临床实践价值。然而，作为综述性研究，其局限性在于缺乏原始研究数据的验证，需要在临床实践中进一步检验其有效性。

---

速递结束，祝您工作愉快！